New study examines stigma toward women who lose weight using GLP-1 medications

Friday, April 17, 2026 – Saturday, April 18 - In a new study exploring stigma associated with the use of GLP-1 drugs for weight loss, women who lost weight using GLP-1 medications were judged more harshly than those who lost weight through diet and exercise, with negative reactions driven largely by beliefs that medication-assisted weight loss is a "shortcut." The study also found higher levels of stigma when the women in sample scenarios were portrayed as white rather than Black.

Lilly’s GLP-1 Foundayo aces MACE in DILI of a phase III

Thursday, April 16, 2026 – Friday, April 17 - Wall Street met with satisfaction but not surprise Eli Lilly and Co.’s undeniably positive top-line results from the phase III Achieve-4 study testing the efficacy and safety of Foundayo (orforglipron) compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk.

GLP-1 in joint fluid may let weight-loss drugs target arthritis directly

Thursday, April 16, 2026 – Friday, April 17 - Arthritis includes a range of conditions that affect the joints, from inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis to more common conditions like osteoarthritis. Many people experience pain, stiffness, and a reduced quality of life. Treatment today focuses on reducing inflammation and relieving symptoms, depending on the type of arthritis. However, researchers from the Department of Biomedicine at Aarhus University have now identified a new possible route for future treatments. Their research is published in The Lancet Rheumatology journal.